Intellectus Partners, LLC - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 397 filers reported holding CRISPR THERAPEUTICS AG in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.

Quarter-by-quarter ownership
Intellectus Partners, LLC ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$388,356
-12.5%
8,556
+8.2%
0.12%
-7.5%
Q2 2023$443,842
+24.9%
7,906
+0.6%
0.13%
+18.8%
Q1 2023$355,326
+14.2%
7,856
+2.6%
0.11%
+3.7%
Q4 2022$311,216
-40.6%
7,656
-4.5%
0.11%
-41.9%
Q3 2022$524,000
-2.4%
8,020
-9.3%
0.19%
+0.5%
Q2 2022$537,000
-13.5%
8,840
-10.6%
0.18%0.0%
Q1 2022$621,000
-24.7%
9,890
-9.2%
0.18%
-11.9%
Q4 2021$825,000
-34.0%
10,890
-2.5%
0.21%
-30.7%
Q3 2021$1,250,000
-30.1%
11,170
+1.1%
0.30%
-24.8%
Q2 2021$1,788,000
+44.3%
11,045
+8.6%
0.40%
+18.5%
Q1 2021$1,239,000
-9.8%
10,170
+13.4%
0.34%
-17.3%
Q4 2020$1,373,000
+73.8%
8,970
-5.0%
0.41%
+37.9%
Q3 2020$790,000
+18.4%
9,445
+4.1%
0.30%
+15.1%
Q2 2020$667,000
+73.7%
9,075
+0.3%
0.26%
+41.5%
Q1 2020$384,000
-6.1%
9,045
+34.6%
0.18%
+10.2%
Q4 2019$409,000
+752.1%
6,720
+397.8%
0.17%
+690.5%
Q1 2019$48,000
+242.9%
1,350
+170.0%
0.02%
+110.0%
Q4 2018$14,000
-36.4%
5000.0%0.01%
+25.0%
Q3 2018$22,000
-42.1%
500
-23.1%
0.01%
-42.9%
Q2 2018$38,000
+442.9%
650
+52.9%
0.01%
+366.7%
Q2 2017$7,000
-22.2%
4250.0%0.00%
-40.0%
Q1 2017$9,000
+28.6%
425
+30.8%
0.01%
+25.0%
Q4 2016$7,0003250.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q4 2022
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$27,989,04633.20%
Gilfoyle Management LLC 100$4,84215.90%
NEA Management Company, LLC 1,587,854$89,142,1246.80%
ARK Investment Management 7,338,447$411,980,3942.73%
Nikko Asset Management Americas, Inc. 3,533,357$198,327,3282.09%
Del-Sette Capital Management, LLC 33,661$1,889,7291.79%
Ikarian Capital, LLC 200,000$11,228,0001.79%
Ikarian Capital, LLC 200,000$11,228,0001.79%
Merlin Capital, Inc 8,802$494,1441.67%
Green Alpha Advisors, LLC 34,373$1,929,7001.27%
View complete list of CRISPR THERAPEUTICS AG shareholders